ArticleESC heart failure2021
History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Diagnostic pathway for cardiac amyloidosis from the healthcare professional's perspective: results from the French DIAM-ATTR survey.Annals of medicine · 2025Article
- The Healthcare Amyloidosis European Registry (HEAR): design of a national registry with a European extension strategy, and foundation of the F-CRIN GRACE network.Orphanet journal of rare diseases · 2025Article
- Beyond the Heart: Exploring Extracardiac Manifestations in Cardiac Amyloidosis for Early Diagnosis.Current cardiology reports · 2025Review
- Dyspnea and Right-Sided Heart Failure in a Patient With a History of Pneumonectomy.CHEST pulmonary · 2025Article
- Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy.ESC heart failure · 2024Article
- A Multidisciplinary Assessment of ChatGPT's Knowledge of Amyloidosis: Observational Study.JMIR cardio · 2024Article
- Case 20: A 69-Year-Old Man With Exertional Dyspnea.Journal of Korean medical science · 2024Article
- Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment.Turk patoloji dergisi · 2024Article
- Unusual presentation of transthyretin (ATTR) cardiac amyloidosis: A case report of pruritus as a possible initial symptom and challenging diagnosis.Clinical case reports · 2023Article
- Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study.Frontiers in cardiovascular medicine · 2023Article
- Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis.Frontiers in cardiovascular medicine · 2023Article
- Early Treatment of Cardiac ATTR: "To Remove the Weeds, You Have to Get the Roots".JACC. CardioOncology · 2022Article
- A Risk Score to Diagnose Cardiac Involvement and Provide Prognosis Information in Patients at Risk of Cardiac Light-Chain Amyloidosis.Frontiers in cardiovascular medicine · 2022Article
- History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsCardiac amyloidosis (CA) has a poor prognosis which is aggravated by diagnostic delay. Amyloidosis extracardiac and cardiac events (AECE and ACE) may help improve CA diagnosis and typing. The aim of this study was to compare AECE and ACE between different CA types and assess their relationship with survival. METHODS AND
resultsThis retrospective cohort study conducted in France from June 2008 to May 2019, at the Henry Mondor Hospital. This cohort included 983 patients with CA. Mean age at inclusion was 73.1 ± 11.4 years, 726 (75.1%) were male and the mean body mass index was 24.5 ± 4.1 kg/m
conclusionsThis study highlights the impact of amyloidosis type and evolution on diagnostic delay and on prognosis. Physicians must be aware and vigilant in front of extracardiac and cardiac events to considerably improve early diagnosis of amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.